Free Trial
→ Musk's shopping list: batteries ✓ solar ✓ data ✓ power ___ (From Behind the Markets) (Ad)tc pixel Free FOCL Stock Alerts

FocalTherics (FOCL) Competitors

$4.65 -0.13 (-2.72%)
As of 04:00 PM Eastern
Compare

FOCL vs. DRTSW, ANZUW, HSCSW, BEATW, and LUCYW

Should you buy FocalTherics stock or one of its competitors? MarketBeat compares FocalTherics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with FocalTherics include Alpha Tau Medical (DRTSW), Anzu Special Acquisition Corp I (ANZUW), Heart Test Laboratories (HSCSW), HeartBeam (BEATW), and Innovative Eyewear (LUCYW). These companies are all part of the "medical equipment" industry.

How does FocalTherics compare to Alpha Tau Medical?

FocalTherics (NASDAQ:FOCL) and Alpha Tau Medical (NASDAQ:DRTSW) are both medical equipment companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, media sentiment, institutional ownership, risk, valuation, dividends and profitability.

62.7% of FocalTherics shares are held by institutional investors. 10.1% of FocalTherics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

FocalTherics presently has a consensus target price of $10.00, suggesting a potential upside of 115.05%. Given FocalTherics' stronger consensus rating and higher probable upside, research analysts clearly believe FocalTherics is more favorable than Alpha Tau Medical.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
FocalTherics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Alpha Tau Medical
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Alpha Tau Medical has a net margin of 0.00% compared to FocalTherics' net margin of -41.47%. Alpha Tau Medical's return on equity of 0.00% beat FocalTherics' return on equity.

Company Net Margins Return on Equity Return on Assets
FocalTherics-41.47% -137.61% -40.62%
Alpha Tau Medical N/A N/A N/A

In the previous week, Alpha Tau Medical had 1 more articles in the media than FocalTherics. MarketBeat recorded 2 mentions for Alpha Tau Medical and 1 mentions for FocalTherics. Alpha Tau Medical's average media sentiment score of 0.43 beat FocalTherics' score of 0.00 indicating that Alpha Tau Medical is being referred to more favorably in the news media.

Company Overall Sentiment
FocalTherics Neutral
Alpha Tau Medical Neutral

Alpha Tau Medical has lower revenue, but higher earnings than FocalTherics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
FocalTherics$70.53M2.47-$29.25MN/AN/A
Alpha Tau MedicalN/AN/AN/AN/AN/A

Summary

FocalTherics beats Alpha Tau Medical on 6 of the 11 factors compared between the two stocks.

How does FocalTherics compare to Anzu Special Acquisition Corp I?

Anzu Special Acquisition Corp I (NASDAQ:ANZUW) and FocalTherics (NASDAQ:FOCL) are both manufacturing companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends.

62.7% of FocalTherics shares are held by institutional investors. 10.1% of FocalTherics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Anzu Special Acquisition Corp I has higher earnings, but lower revenue than FocalTherics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Anzu Special Acquisition Corp IN/AN/AN/AN/AN/A
FocalTherics$70.53M2.47-$29.25MN/AN/A

Anzu Special Acquisition Corp I has a net margin of 0.00% compared to FocalTherics' net margin of -41.47%. Anzu Special Acquisition Corp I's return on equity of 0.00% beat FocalTherics' return on equity.

Company Net Margins Return on Equity Return on Assets
Anzu Special Acquisition Corp IN/A N/A N/A
FocalTherics -41.47%-137.61%-40.62%

In the previous week, FocalTherics had 1 more articles in the media than Anzu Special Acquisition Corp I. MarketBeat recorded 1 mentions for FocalTherics and 0 mentions for Anzu Special Acquisition Corp I. Anzu Special Acquisition Corp I's average media sentiment score of 0.00 equaled FocalTherics'average media sentiment score.

Company Overall Sentiment
Anzu Special Acquisition Corp I Neutral
FocalTherics Neutral

FocalTherics has a consensus target price of $10.00, suggesting a potential upside of 115.05%. Given FocalTherics' stronger consensus rating and higher possible upside, analysts clearly believe FocalTherics is more favorable than Anzu Special Acquisition Corp I.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Anzu Special Acquisition Corp I
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
FocalTherics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Summary

FocalTherics beats Anzu Special Acquisition Corp I on 7 of the 10 factors compared between the two stocks.

How does FocalTherics compare to Heart Test Laboratories?

FocalTherics (NASDAQ:FOCL) and Heart Test Laboratories (NASDAQ:HSCSW) are both medical equipment companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, profitability, analyst recommendations, dividends, valuation, earnings and risk.

Heart Test Laboratories has lower revenue, but higher earnings than FocalTherics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
FocalTherics$70.53M2.47-$29.25MN/AN/A
Heart Test Laboratories$8.67KN/AN/AN/AN/A

Heart Test Laboratories has a net margin of 0.00% compared to FocalTherics' net margin of -41.47%. Heart Test Laboratories' return on equity of 0.00% beat FocalTherics' return on equity.

Company Net Margins Return on Equity Return on Assets
FocalTherics-41.47% -137.61% -40.62%
Heart Test Laboratories N/A N/A N/A

In the previous week, FocalTherics and FocalTherics both had 1 articles in the media. Heart Test Laboratories' average media sentiment score of 1.87 beat FocalTherics' score of 0.00 indicating that Heart Test Laboratories is being referred to more favorably in the news media.

Company Overall Sentiment
FocalTherics Neutral
Heart Test Laboratories Very Positive

FocalTherics presently has a consensus target price of $10.00, indicating a potential upside of 115.05%. Given FocalTherics' stronger consensus rating and higher possible upside, equities research analysts plainly believe FocalTherics is more favorable than Heart Test Laboratories.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
FocalTherics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Heart Test Laboratories
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

62.7% of FocalTherics shares are owned by institutional investors. 10.1% of FocalTherics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

FocalTherics beats Heart Test Laboratories on 6 of the 10 factors compared between the two stocks.

How does FocalTherics compare to HeartBeam?

HeartBeam (NASDAQ:BEATW) and FocalTherics (NASDAQ:FOCL) are both medical equipment companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, earnings, profitability, dividends, media sentiment and analyst recommendations.

FocalTherics has a consensus price target of $10.00, suggesting a potential upside of 115.05%. Given FocalTherics' stronger consensus rating and higher possible upside, analysts clearly believe FocalTherics is more favorable than HeartBeam.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
HeartBeam
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
FocalTherics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

HeartBeam has a net margin of 0.00% compared to FocalTherics' net margin of -41.47%. HeartBeam's return on equity of 0.00% beat FocalTherics' return on equity.

Company Net Margins Return on Equity Return on Assets
HeartBeamN/A N/A N/A
FocalTherics -41.47%-137.61%-40.62%

In the previous week, HeartBeam had 1 more articles in the media than FocalTherics. MarketBeat recorded 2 mentions for HeartBeam and 1 mentions for FocalTherics. HeartBeam's average media sentiment score of 0.44 beat FocalTherics' score of 0.00 indicating that HeartBeam is being referred to more favorably in the media.

Company Overall Sentiment
HeartBeam Neutral
FocalTherics Neutral

HeartBeam has higher earnings, but lower revenue than FocalTherics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
HeartBeamN/AN/AN/AN/AN/A
FocalTherics$70.53M2.47-$29.25MN/AN/A

62.7% of FocalTherics shares are held by institutional investors. 10.1% of FocalTherics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

FocalTherics beats HeartBeam on 6 of the 11 factors compared between the two stocks.

How does FocalTherics compare to Innovative Eyewear?

FocalTherics (NASDAQ:FOCL) and Innovative Eyewear (NASDAQ:LUCYW) are both medical equipment companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, profitability, earnings, valuation, institutional ownership, analyst recommendations, dividends and risk.

In the previous week, FocalTherics and FocalTherics both had 1 articles in the media. Innovative Eyewear's average media sentiment score of 1.92 beat FocalTherics' score of 0.00 indicating that Innovative Eyewear is being referred to more favorably in the news media.

Company Overall Sentiment
FocalTherics Neutral
Innovative Eyewear Very Positive

FocalTherics currently has a consensus target price of $10.00, suggesting a potential upside of 115.05%. Given FocalTherics' stronger consensus rating and higher probable upside, analysts clearly believe FocalTherics is more favorable than Innovative Eyewear.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
FocalTherics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Innovative Eyewear
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Innovative Eyewear has lower revenue, but higher earnings than FocalTherics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
FocalTherics$70.53M2.47-$29.25MN/AN/A
Innovative Eyewear$2.98MN/AN/AN/AN/A

62.7% of FocalTherics shares are owned by institutional investors. 10.1% of FocalTherics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Innovative Eyewear has a net margin of 0.00% compared to FocalTherics' net margin of -41.47%. Innovative Eyewear's return on equity of 0.00% beat FocalTherics' return on equity.

Company Net Margins Return on Equity Return on Assets
FocalTherics-41.47% -137.61% -40.62%
Innovative Eyewear N/A N/A N/A

Summary

FocalTherics beats Innovative Eyewear on 6 of the 10 factors compared between the two stocks.

Get FocalTherics News Delivered to You Automatically

Sign up to receive the latest news and ratings for FOCL and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

FOCL vs. The Competition

Export
MetricFocalThericsSurgical, Medical, And Dental Instruments And Supplies IndustryManufacturing SectorNASDAQ Exchange
Market Cap$179.16M$2.64B$4.34B$12.54B
Dividend YieldN/AN/A6.83%5.30%
P/E RatioN/A1.8021.7926.71
Price / Sales2.47542.21234.2894.04
Price / CashN/A3.6357.5237.62
Price / Book8.946.7232.696.78
Net Income-$29.25M-$72.25M$111.12M$337.19M
7 Day PerformanceN/A-3.06%0.61%2.63%
1 Month PerformanceN/A-4.71%4.65%6.60%
1 Year PerformanceN/A42.40%17.11%37.90%

FocalTherics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
FOCL
FocalTherics
N/A$4.65
-2.7%		$10.00
+115.1%		N/A$179.16M$70.53MN/A230
DRTSW
Alpha Tau Medical
N/A$1.97
-16.0%		N/A+998.1%$0.00N/AN/A80
ANZUW
Anzu Special Acquisition Corp I
N/A$0.05
flat		N/A-29.0%$0.00N/AN/A2
HSCSW
Heart Test Laboratories
N/A$0.08
+56.8%		N/A-17.2%$0.00$8.67KN/A10
BEATW
HeartBeam
N/A$0.06
-9.5%		N/A-88.4%$0.00N/AN/A5

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:FOCL) was last updated on 6/2/2026 by MarketBeat.com Staff.
From Our Partners
A gold storm is coming – are you ready?
The U.S. Treasury Secretary is betting big on gold - and the world's most successful investors are following s...
Traders Agency | Sponsoredtc pixel
Gold hit $4,500 - but these miners haven't caught up yet
$9 trillion in U.S. debt must be refinanced in 2026 - at current rates - while the largest foreign buyers of T...
Golden Portfolio | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
President Trump just sparked a stock market MELT UP
The real reason Musk, Huang, Cook, and Fink just flew to Beijing Last week, the CEOs of Nvidia, Apple, Spac...
Stansberry Research | Sponsoredtc pixel
The REAL Reason Trump is Invading Iran
For a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...
Banyan Hill Publishing | Sponsoredtc pixel
Giving “2022 pre-ChatGPT” vibes (but 10x bigger)
When ChatGPT launched in 2022, Nvidia surged 1,800% over three years. Now, Nvidia's CEO suggests July 22nd cou...
StocksToTrade | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel